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Summary To assess the role of oestrogen regulation in the growth of ovarian cancer, we examined the effects
of an oestrogen, 17 P-oestradiol, and an anti-oestrogen, tamoxifen, on oestrogen receptor (ER) -positive and
-negative human ovarian carcinoma cell lines. As measured by a dextran-coated charcoal adsorption assay, cell
lines PEOI, PEO4 and PEO6 possessed moderate concentrations of ER (96-132 fmol mg-' protein), PEAl
and PEA2 had low values (12-23fmol mg-' protein) and PEO14, T014, PE023 and PEO16 were ER-
negative.
Addition of 17 P-oestradiol (10 nm or 0.1 nM) to the ER +ve cell line, PEO4, increased the growth rate.
This oestrogen stimulation could be blocked by I gtM tamoxifen. In contrast, the growth rate of the ER -ve
cell line PEO14 was unaffected by the addition of 17 P-oestradiol or tamoxifen.
Concentrations of tamoxifen in excess of 8 ytM were required to produce complete cytostasis in all lines. This
concentration of tamoxifen over 72 hours also inhibited 50% colony formation when cells were plated on
plastic.
These data indicate that some ovarian carcinoma cell lines contain ER and their growth can be sensitive to
oestrogen and anti-oestrogen modulation.
The role of oestrogen in the growth of ovarian cancer is
unclear. The presence of oestrogen receptors (ER) in the
majority of ovarian tumours (Pollow et al., 1983; Jones et al.,
1983; Ford et al., 1983; Slotman & Rao, 1988) suggests that
the growth of ovarian cancer cells may be altered by oest-
rogen stimulation. Furthermore, several small clinical trials
investigating treatment of ovarian cancer with the anti-
oestrogen tamoxifen have reported response rates of between
6% and 36% (Schwartz et al., 1982; Pagel et al., 1983;
Hamerlynck et al., 1985; Campbell et al., 1984), although
others have failed to demonstrate such benefits (Osborne et
al., 1988; Slevin et al., 1986; Shirey et al., 1984; Landoni et
al., 1983).
We have recently derived and characterized a series of
human ovarian carcinoma cell lines (Langdon et al., 1988).
In the present study, we measured the levels of ER in these
lines and examined the effects of 17P-oestradiol and the
anti-oestrogen tamoxifen on the growth of two of these lines
- the ER +ve line PE04 and the ER -ve line, PE014. We
have also assessed the effects of high doses of tamoxifen on 8
of the lines of the series.
Materials and methods
Cell lines and drugs
The characterization of the cell lines has been described
previously (Langdon et al., 1988) but brief details are
recorded in Table I. Cell lines were routinely cultured at
37°C, 90% humidity and 5% CO2 in RPMI 1640 + fetal
calf serum (FCS) (9:1) with streptomycin (100 gg ml-'),
glutamine (2 mM), pyruvate (2 mM), penicillin (100 IU ml-'),
and 3-[morpholino] propane sulphonic acid (12.5 mM,
pH 7.4).
17 P-oestradiol was obtained from Sigma Ltd., Dorset, UK
and tamoxifen was a gift from ICI Pharmaceuticals Ltd.,
Macclesfield, UK. In the cell growth experiments, both were
initially dissolved in ethanol. The final concentration of
ethanol in cell growth experiments was always less than
0.01% v/v, a concentration previously shown to have no
effect on these cell lines.
Oestrogen receptor assays
Assays were performed on cells which were in early plateau
phase of their growth using the dextran-coated charcoal
adsorption method described previously (Hawkins et al.,
1975; Hawkins et al., 1981). Cell lines were considered
ER +ve if the ER content was greater than 5 fmol mg-'
protein.
Cellgrowth assays
To determine the effect of 17 P-oestradiol and tamoxifen on
the growth rate of the PE04 and PE014 lines, cells were
plated at a density of 4 x 104 per well in 6-well plates in
FCS + RPMI 1640 (1:9). After 48 hours, the medium was
changed to charcoal-stripped FCS (Stanley et al., 1977) +
RPMI 1640 (1:9), with or without 17 P-oestradiol, or tamox-
ifen, or both. Initial experiments indicated that growth of
PE04 and PE014 cells in charcoal-stripped serum was
independent of whether or not phenol red indicator was
present in the medium. Cells were refed with fresh medium
containing drug every three days. At the appropriate times
cells were trypsinised from plastic and counted in a ZF
Coulter Counter. Each experiment was repeated at least
twice.
In the cytostasis experiments, tamoxifen [1 to 32 gM in a
medium containing RPMI 1640 + unstripped FCS (9:1)] was
added when the cell density was approximately 2 x 10' per
well. The cells were refed with fresh medium containing
tamoxifen after 4 days and after 7 days cells were trypsinised
and counted. The cytostatic concentration of tamoxifen was
that which left the cell number unchanged over a 7-day time
course, whilst untreated control cells continued to grow.
Uptake ofradiolabelled thymidine
Cells growing on plastic in 35 mm 6-well tissue culture dishes
were pulsed with ltCi ml-' [methyl-3H]-thymidine (Amer-
sham, UK) for 2 hours at 37°C. Cells were then trypsinised
and washed on to glass fibre filters (GF/A Whatman) with
5% trichloroacetic acid. The filters were dried and counted
on a Packard Tri-Carb 1900CA liquid scintillation analyzer
using Unisolve 1 (10 ml per tube) (Koch-Light Ltd) as the
scintillant.
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Clonogenicity experiments
Cells were plated in 6-well plates at a cell number known to
produce approximately 100 colonies per well. After 3 days,
tamoxifen was added at concentrations ranging from 1 i1M to
32 tM for 72 hours. The drug was then removed and the
plates incubated as described above. Plates were refed every 3
days with medium containing RPMI 1640 + unstripped
FCS (9:1). After 3 to 5 weeks, depending on the cell line,
colonies (> 50 cells) were counted. The concentrations pro-
ducing 50% and 90% inhibitions of colony formation
relative to controls not exposed to the drug (IC50 and IC90
values) were then calculated. Triplicate wells were studied for
each drug concentration and experiments repeated at least
once to confirm the value.
Results
Oestrogen receptors
The concentration of ERs for each cell line is recorded in
Table I. Cell lines were derived from four patients; PEO1,
PEO4 and PEO6 from patient DB, PEAl and PEA2 from
patient MK; PEO16 from patient ER and PEO14, T014 and
PE023 from patient EM. Cell lines derived from the same
individual had similar concentrations of receptors. This was
irrespective of previous treatment. Thus PEOl, PEO4 and
PEO6 possessed higher concentrations of receptors than
PEAl and PEA2 whereas PEG14, T04 and PE023 and also
PEG16 were receptor negative.
Effect of 17P-oestradiol and tamoxifen on cellgrowth
Addition of 17P-oestradiol at either 0.1 nM or 1O nM to
PEO4 cells growing in charcoal-stripped FCS markedly
stimulated the growth rate, with a slightly greater effect being
produced at the higher dose (Figure 1). This increased
growth rate was similar to the growth rate of PEO4 cells in
the presence of unstripped FCS (shown for days 4 and 7 in
Figure 1). The stimulation by 0.1 nM 17 P-oestradiol could be
completely blocked by simultaneous addition of 1 tiM tamox-
ifen (Figure 1). Since 1 0tM tamoxifen alone had no effect on
control cells (Figure 1), this suggests that at this dose it acts
only as a competitive inhibitor of oestrogen.
To corroborate these effects of oestrogen and anti-































Figure 1 Effect of 17 P-oestradiol and tamoxifen on the growth
of the ER + ve PEO4 ovarian carcinoma cell lines; O
Charcoal-stripped FCS + phenol red-free RPMI 1640 (1:9) (FCS/
RPMI); --O-- FCS/RPMI + 10 nM 17 P-oestradiol;
FCS/RPMI + 0.1 nm 17p-oestradiol; --A- - FCS/RPMI
+ 0.1 nM 17 P-oestradiol + I m tamoxifen; .........A.. FCS/
RPMI + 1 ItM tamoxifen; --- -- Unstripped FCS + phenol
red-free RPMI 1640 (1:9); **P<0.0001 and * 0.01 <P<0.05
for the difference between FCS/RPMI group and group
indicated. For all other points, the difference was not significant
at P<0.05 value. Error bars= I standard deviation.
Table I Origin and ER status of the 9 cell lines produced from 4 patients with ovarian
adenocarcinoma
Morphology of Previous Passage ER
Cell line Patient primary tumour Sitea treatment" numberc concentrationd
PEOI Poorly PA CDDP+, 5-FU, p77-p82 96 (73-145)
differentiated chlorambucil
PEO4 DB serous PA " p52-p63 112 (60-203)
adenocarcinoma
PEO6 PA " p12-p16 132 (78-185)
PEAl Poorly PE None pl0-pl5 23
MK differentiated
PEA2 adenocarcinoma PA CDDP, prednimustine p5-plO 12
Poorly
PEG16 ER differentiated PA Radiotherapy p9-pl4 0
serous
adenocarcinoma
PEO14 Well PA None p8-p13 0 (0-2)
differentiated
T014 EM serous SM " p7-p13 0
adenocarcinoma
PE023 PA CDDP, chlorambucil p4-p13 0
aPA = Peritoneal ascites; PE = Pleural effusion; SM = solid metastasis, bCDDP =cis-platinum and
5-FU = 5-fluorouracil, cPassage numbers used for ER measurements and in growth experiments, dValues
expressed in fmol mg-' protein. Median value shown for PEO1, PEO4, PEO6 and PEO14 based on 3
independent measurements. Range ofvalues measured shown in brackets. Other cell lines were measured
once.
- I I ::
t "
.7 i





'. 4 .1 '. !-.:. ....OESTROGEN AND GROWTH OF OVARIAN CANCER CELL LINES 215
PEO4 cells were pulsed with 3H-thymidine for 2 hours
(Figure 2). After 4 days exposure to 17p-oestradiol, 3H-
thymidine incorporation into the wells of PEO4 cells was
increased approximately 100% relative to the control group
and this increased to approximately 280% at 7 days (Figure
2). Again this effect was totally inhibited by tamoxifen while
tamoxifen alone had no significant effect.
In contrast, the growth of the ER -ve PEO14 cell line was
unaffected by addition of 17 ,B-oestradiol or tamoxifen
(Figure 3). 3H-Thymidine uptake into the different groups of
PEO14 cells was also unchanged by the presence or absence
of 17p-oestradiol or tamoxifen (data not shown).
Effect ofhigh-dose tamoxifen on cellgrowth
To examine the cytostatic effects of tamoxifen, the cell lines
were exposed to concentrations varying from I to 32 JM over
7 days. The selection of this dose range was based on a
previous study which had investigated ER + ve and ER -ve
breast carcinoma cell lines (Reddel et al., 1985). Doses
greater than 8 JAM were required to produce complete cyto-
stasis in our ovarian cell lines (Table II). There was no
difference between ER + ve and ER -ve cell lines in their
response to these high doses of tamoxifen.
To study the cytotoxic effects of tamoxifen, a colony-
forming assay on plastic was used. Cell lines were exposed to
tamoxifen for 72 hours and the IC50 dose varied between 5
and 11 JAM (Table II). Again there was no significant
difference between ER +ve and ER -ve lines.
Discussion
Results from clinical trials have yielded conflicting data as to
the potential role of anti-oestrogen therapy for the treatment
of ovarian cancer (Schwartz et al., 1982; Pagel et al., 1983;
Hamerlynck et al., 1985; Campbell et al., 1984; Osborne et
al., 1988; Slevin et al., 1986; Shirey et al., 1984; Landoni et
al., 1983). To assess further the role of such therapy, we have
examined the effects of oestrogen and tamoxifen on the





























CONT 10 nM E2 0.1 nM E2 0.1 nM E2
+ 1 ,uM T
1 pMT
Figure 2 Uptake of 3H-thymidine into DNA of PE04 cells.
Cont = charcoal-stripped FCS + phenol red-free RPMI 1640 (1:9)
(FCS/RPMI) 10 nm E2 = FCS/RPMI + 10 nM 17 P-oestradiol;
0.1 nM E2 = FCS/RPMI + 0.1 nM 17P-oestradiol; 0.1 nM
E2 + 1 JAM T = FCS/RPMI + 0.1 nM 17 P-oestradiol + I JuM tam-
oxifen; 1 JAM T = FCS/RPMI + 1 JAM tamoxifen *P<0.05 for the
difference between control group (charcoal stripped FCS +
phenol red free RPMI 1640 (1:9)) and the group indicated. For





Figure 3 Effect of 17 P-oestradiol and tamoxifen on the growth
of the ER -ve PEO14 ovarian carcinoma cell line;
Charcoal-stripped FCS + phenol red-free RPMI 1640 (1:9) (FCS/
RPMI); --O-- FCS/RPMI + 10 nM 17 P-oestradiol;
FCS/RPMI + 0.1 nM 17 P-oestradiol; ---A ---FCS/RPMI +
0.1 nM 17 P-oestradiol + I jAM tamoxifen; .......A. FCS/
RPMI + I JLM tamoxifen. For all points shown P>0.04 for the
difference between FCS/RPMI group and any other group. Error
bars = I standard deviation.
Table II Effect of tamoxifen on 8 ovarian carcinoma cell lines
Concentration oftamoxifen ("lM) for
ER CytostasiSb Cytotoxicityf
Cell line status over 7days IC50 IC90
PEOI + 8 8 13
PEO4 + 12 8 13
PEO6 + 9 6 12
PEAI + 12 9 15
PEA2 + 13 10 16
PEO14 - 12 8 13
T014 - 13 8 11
PE023 - 14 1 1 15
a+ >5 fmolmg-' protein, bDose to keep cell number constant,
cDose to inhibit colony formation. IC5 = 50% inhibition of colony
formation:IC%0 = 90% inhibition ofcolony formation. Values are fora
72-hour exposure to tamoxifen.
lines. Since the ER protein is believed to mediate the growth-
modulating effects of oestrogen and tamoxifen in at least
breast carcinoma, ER status is potentially important in deter-
mining response to these agents in ovarian cancer. The series
of ovarian carcinoma cell lines used in this study (Langdon et
al., 1988) had a range of ER concentrations varying from
0 to 200 fmol mg-' protein. Each group of cell lines derived
from the same patient possessed similar concentrations of
ERs, although the lines were derived at different stages of
treatment.
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The influence of 17 P-oestradiol on the growth of an ER
+ ve cell line, PE04, was examined to determine if there was
evidence of oestrogen-sensitivity. Extrapolating from studies
with breast cell lines, oestrogen-sensitivity is most clearly
indicated under conditions where levels of oestrogen are first
reduced in the growth medium (Reddel et al., 1984; Suther-
land et al., 1983). Addition of 17P-oestradiol to charcoal-
stripped serum enhanced the growth rate of PE04 cells
indicating sensitivity to oestrogen. This oestrogenic stimulus
could be inhibited by the simultaneous presence of 1 IJM
tamoxifen, providing further support that this is an ER-
mediated event. However, the PE04 cell line still grows
under conditions where an oestrogenic stimulus is markedly
reduced, that is, in phenol red-free medium containing
charcoal-stripped serum. Also the presence, or absence, of
phenol red appeared to have no effect on the growth rate of
this cell line. It is possible that there is residual oestrogen
after charcoal-stripping and that this is effective. However,
the addition of tamoxifen alone to PE04 cells under these
conditions did not produce further inhibition. Thus the cell
line, while being oestrogen-sensitive, appears not to be
oestrogen-dependent. The growth of PE014 cells, on the
other hand, was not stimulated by oestrogen, or inhibited by
anti-oestrogen, a property which is consistent with its lack of
ERs.
In the case of breast cancer, tamoxifen at doses greater
than 5lM is equally cytotoxic and cytostatic to cell lines,
irrespective of ER content (Reddel et al., 1985). The response
of our ovarian lines to high levels of tamoxifen was examined
in two ways. The cytotoxic effects of the drug were examined
in a clonogenic assay. Doses of 5 to 11 JiM were toxic
(measured as the IC5o) for all lines, whether ER + ve or
ER-ve. This is also the dose range reported for cytotoxicity
to a series of 13 breast carcinoma cell lines (Reddel et al.,
1985). In cell growth assays, doses of tamoxifen greater than
8 g.m were needed to prevent increase in the cell number.
Again ER + ve cell lines responded no differently from ER
-ve lines. These concentrations affecting cell growth in vitro
are above the maximum blood concentration of approx-
imately 1 tLM that can be achieved in vivo, even when a
loading dose of tamoxifen, to enhance blood and tumour
levels, is used (Fabian et al., 1981). In two previous studies,
where ovarian carcinoma samples were grown in agar, in-
creased concentrations of tamoxifen produced increased
inhibition of colony formation, but this, too, was indepen-
dent of ER status (Runge et al., 1986a; 1986b). In another
study, only 2 of 4 ovarian tumour samples which contained
an ER concentration of greater than 30 fmol mg-' protein
responded to a continuous exposure of 2ylM tamoxifen; all
14 samples with an ER content less than 30 fmolmg'- pro-
tein showed no response (Lazo et al., 1984). These studies,
together with our own, suggest that high levels of tamoxifen
are needed to have a major inhibitory effect on the growth of
ovarian carcinoma in vitro. As seen in this study with PEO4
cells, even when tamoxifen is able to antagonise completely
oestrogen-stimulated growth, there remains an oestrogen-
independent growth component which can only be abolished
by very high concentrations of tamoxifen.
In conclusion, these series of cell lines represent a model
system to assess further the role of endocrine therapy in
ovarian cancer. To the best of our knowledge, they represent
the first ovarian carcinoma cell lines reported with ER con-
centrations greater than 30 fmol mg-' protein (Hamilton et
al., 1983). As such, they are being used to help define the
mechanisms by which oestrogen can modify growth in
ovarian cancer.
We wish to thank Miss Amanda McDonald for assistance with
growing the cell lines.
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